CJC-1295 + Ipamorelin + Tesamorelin + IGF-1 LR3 - Atlas

1 Identity

Fixed-ratio four-component article: a 30-residue peptide-maleimide conjugate, a five-residue pentapeptide amide with two non-proteinogenic residues, an N-acylated 44-residue peptide amide, and an 83-residue recombinant refolded protein with three intramolecular disulfides, co-lyophilized. Two of the four are GHRH(1-29)-family molecules on the same scaffold and one is a folded protein, which together set the analytical class of the whole article. A brand name states no composition and no ratio and is not accepted alone on a certificate or a specification. As with every CJC-1295 title, the second name is ambiguous - the DAC-bearing conjugate at 3,647.250 Da against CJC-1295 no DAC, trade usage for Modified GRF (1-29) at 3,367.954 Da - so this record is written for the DAC-bearing conjugate and the specification names it in full.

Contains CJC-1295 + Ipamorelin + Tesamorelin + IGF-1 LR3

Sequence

Stated per component; the full sequences live on the component records and are not restated here. The blend-relevant facts are these. CJC-1295 (DAC:GRF) is the tetrasubstituted GHRH(1-29) scaffold plus Lys30 bearing a 3-maleimidopropionyl group. Tesamorelin is the trans-3-hexenoyl-capped 44-mer amide, sharing 27 of the first 29 positions with it. Ipamorelin is Aib-His-D-2-Nal-D-Phe-Lys-NH2. IGF-1 LR3 is a 13-residue leader fused to human IGF-1(1-70) carrying Glu3Arg, 83 residues in total, so the mature segment begins GPR- and not GPE-, with six cysteines and three disulfides at Cys19-Cys61, Cys60-Cys65 and Cys31-Cys74 in 83-residue numbering.

Molecular formula

Stated per component. A mixture has no combined formula and none is written. CJC-1295 (DAC:GRF) C165H269N47O46. Ipamorelin C38H49N9O5. Tesamorelin C221H366N72O67S as the free base, supplied as the acetate. IGF-1 LR3 C400H619N111O115S9 with all three disulfides formed, C400H625N111O115S9 fully reduced. Counterion is a measured finding per component, and the protein is not a simple peptide salt: it is supplied either as a lyophilized free base or in an acetate-buffered matrix, and which one is a specification statement rather than an assumption.

Average mass

Per component: CJC-1295 (DAC:GRF) 3,647.250 Da; ipamorelin 711.868 Da; tesamorelin 5,135.856 Da as the free base; IGF-1 LR3 9,111.55 Da oxidized and 9,117.60 Da fully reduced, the +6.05 Da gap being the arithmetic that proves three disulfides are formed. AT A nominal 10 mg + 10 mg + 10 mg + 1 mg fill, 31 mg total, the molar amounts are 2.74179, 14.04755, 1.94710 and 0.10975 micromol, a ratio of 24.98 : 127.99 : 17.74 : 1.00 against the protein. A 1 mg protein in a 31 mg fill is a trace constituent by mole count, whatever a trade document calls it, and a 12.8-fold molecular-weight spread across four components makes any mass-based description of this article as balanced simply wrong.

Monoisotopic mass

Per component, and monoisotopic is not the release measurement on the protein. CJC-1295 3,645.01548, [M+3H]3+ 1,216.0124. Ipamorelin 711.3857, [M+H]+ 712.3930. Tesamorelin 5,132.71664, used with a deconvoluted envelope. IGF-1 LR3 9,105.3487 oxidized and 9,111.3957 reduced, quoted as reference values because at 9 kDa the monoisotopic peak is not the base peak of the isotope envelope; a usable certificate reports a deconvoluted average with the charge-state series printed. The mass test the protein defeats: scrambled-disulfide isomers are exactly isobaric with correctly folded material and frequently co-elute, so only peptide-map disulfide connectivity distinguishes them. Two further named species are required output: des-acyl tesamorelin at -96.058 Da and the maleamic-acid degradant at +18.015 Da. No single blend molecular weight is printed.

Salt / variant note

(1) scrambled-disulfide isomers of the protein: exactly isobaric, frequently co-eluting, the principal quality variable in refolded material and invisible to mass and RP-HPLC alike. (2) the fully reduced protein at +6.05 Da. (3) the construct fork: IGF-1 LR3 against IGF-1 des(1-3) and native IGF-1(1-70), the GPE- against GPR- mature N-terminus being the check. (4) the DAC fork: 3,647.250 against 3,367.954. (5) des-acyl tesamorelin at -96.058 Da, together with the isobaric acyl isomers, which the mass alone will not separate. (6) Counterion per component; ratio not standardized across listings.

2 Class & testing panel

Form

Fixed-ratio blend

Testing panel

P3, P2 and P4 — panel definitionas a union, run per component and never once for the vial. P3 is engaged twice - D-Ala2 in CJC-1295, and Aib1, D-2-Nal3 and D-Phe4 in ipamorelin - so chiral amino acid analysis runs against each component's own expected D-content and is never pooled; the other two components contain no D-residue and no chiral limit is written for them. P2 governs tesamorelin's acyl group, and des-acyl material is reported as a named species. P4 governs the recombinant protein and brings disulfide connectivity mapping, host-cell protein, host-cell DNA, endotoxin, aggregate content by size-exclusion chromatography and an expression-host declaration, attributes no peptide panel carries. The conjugate adds intact maleimide content and a free-thiol determination. This is the worst-conditioned article in the group for amino acid analysis: the recombinant protein contributes seven prolines, three methionines and seven glycines to a vial that already holds two GHRH(1-29)-family molecules, which leaves neither tesamorelin nor CJC-1295 with a unique marker residue, and both are then reachable only through a difference chain three deep that rests on the 1 mg component

3 Primary sources & evidence

The index reports the design and provenance of the literature, not a conclusion about effect.

What follows reports study design and provenance, not a conclusion about effect. Literature exists for each component and sits on that component's own record in this catalog. The tesamorelin record rests on registrational trials, cited by identifier: Falutz et al., N Engl J Med 2007;357:2359-2370, PMID 18057338, DOI 10.1056/NEJMoa072375; and Falutz et al., J Clin Endocrinol Metab 2010;95:4291-4304, PMID 20554713, DOI 10.1210/jc.2010-0490. The protein component's record rests substantially on cell-culture and bioprocess literature rather than on clinical designs. Combination literature: none identified. No published study of this fixed four-component combination at any ratio was identified; that is a statement about the published record and not a conclusion about any component.

4 Storage & specification

Storage

Co-lyophilized solid in Type I amber glass with a nitrogen headspace, desiccated and light-protected, stored at -20 degrees C plus or minus 5 degrees C. Non-sterile laboratory chemical, no sterility claim. The protein governs the handling rules: repeated freeze-thaw is the aggregation pathway for refolded material, so the article is subdivided once into single-use units rather than thawed and refrozen. Two further written conditions follow from the chemistry rather than from convention. Water is a reactant here, not just a specification line, because the maleimide hydrolyzes in its presence, which makes Karl Fischer determination a release attribute. And free thiols and reducing agents are incompatible with this article on two counts at once, being a quench for the maleimide and a reductant for the protein's three disulfides; the incompatibility is carried on the label.

Shelf life

Provisional 24 months at -20 degrees C plus or minus 5 degrees C, desiccated and light-protected, with a mandatory interim pull on each of the first three lots. The retest-limiting attributes are split between two chemistries that do not usually share a vial: maleimide hydrolysis to the maleamic acid at +18.015 Da on the conjugate, and protein attributes, namely aggregate content by size-exclusion chromatography and disulfide scrambling by non-reduced peptide map. Des-acyl tesamorelin at -96.058 Da follows those, with per-component net content, the measured ratios, water and counterion trended alongside. The blend runs its own protocol and inherits no component study.